Marinus Pharmaceuticals (NASDAQ:MRNS) Given “Overweight” Rating at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note released on Monday, Benzinga reports. Cantor Fitzgerald currently has a $13.00 price objective on the biopharmaceutical company’s stock.

Several other equities analysts also recently commented on MRNS. LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a buy rating to a neutral rating in a report on Wednesday, August 14th. Truist Financial reissued a buy rating and issued a $10.00 price target on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. HC Wainwright reiterated a buy rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. Finally, StockNews.com cut shares of Marinus Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, August 22nd. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of Hold and a consensus target price of $10.25.

Marinus Pharmaceuticals Trading Down 0.7 %

Shares of NASDAQ:MRNS opened at $1.39 on Monday. The company has a current ratio of 2.28, a quick ratio of 2.15 and a debt-to-equity ratio of 5.68. The stock has a market capitalization of $76.56 million, a PE ratio of -0.53 and a beta of 1.13. Marinus Pharmaceuticals has a 1 year low of $1.05 and a 1 year high of $11.26. The firm has a fifty day moving average price of $1.34 and a 200 day moving average price of $3.22.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.01). The company had revenue of $8.06 million for the quarter, compared to the consensus estimate of $9.05 million. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. During the same quarter last year, the company posted ($0.61) EPS. Analysts expect that Marinus Pharmaceuticals will post -1.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Trexquant Investment LP bought a new stake in shares of Marinus Pharmaceuticals in the fourth quarter valued at about $553,000. Franklin Resources Inc. lifted its stake in shares of Marinus Pharmaceuticals by 1.3% in the fourth quarter. Franklin Resources Inc. now owns 3,833,955 shares of the biopharmaceutical company’s stock valued at $41,675,000 after buying an additional 49,589 shares during the period. Campbell & CO Investment Adviser LLC bought a new stake in shares of Marinus Pharmaceuticals in the fourth quarter valued at about $1,146,000. Superstring Capital Management LP bought a new stake in shares of Marinus Pharmaceuticals in the fourth quarter valued at about $5,027,000. Finally, Wellington Management Group LLP lifted its stake in shares of Marinus Pharmaceuticals by 54.8% in the fourth quarter. Wellington Management Group LLP now owns 241,299 shares of the biopharmaceutical company’s stock valued at $2,623,000 after buying an additional 85,455 shares during the period. 98.80% of the stock is currently owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.